John J.P. Kastelein, MD

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Regeneron(MODEST), CSL Behring(SIGNIFICANT), Madrigal(SIGNIFICANT), CiVi Biopharma(SIGNIFICANT), Esperion Therapeutics(SIGNIFICANT), North Sea Therapeutics(MODEST), Draupnir(SIGNIFICANT), Matinas BioPharma(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Pfizer(MODEST), Menarini(NONE), Novartis(MODEST), Omeicos(SIGNIFICANT), Silence Therapeutics(SIGNIFICANT), Sirnaomics(SIGNIFICANT) OFFICER, DIRECTOR ETC: NewAmsterdam Pharma(SIGNIFICANT), Staten Biotech(SIGNIFICANT)

View Full Disclosure